Answers are grounded in this paper and cite their sources.
Background: Allergic asthma (AA) is a chronic respiratory disease closely linked to immune-inflammatory responses driven by M2 macrophage polarization. PrimO-glucosylcimifugin (POG), a natural bioactive compound from Saposhnikovia divaricata (SD), alleviates inflammation in acute lung injury mice, but whether it mitigates AA by modulating M2 macrophage polarization remains unclear. Objective: This study investigated POG’s effects on AA and its mechanisms in regulating M2 macrophage polarization. Methods: LC-MS profiled the SD/Prunus mume (PM) combination, and network pharmacology predicted its main active components and key anti-AA mechanisms. Ovalbumin (OVA) plus IL-4 established AA models in mice and RAW264.7 cells. Lung protection was assessed by histopathology, lung indices, and type II immune inflammatory cytokine markers. Flow Cytometry, RT-qPCR, immunofluorescence, and Western blot examined key genes/proteins in the JAK2-STAT6-PPARγ axis. Results: LC-MS-based network pharmacology identified POG as the key SD/PM active ingredient alleviating AA. Pharmacodynamic evaluation showed POG effectively alleviated OVA-induced airway inflammation and pulmonary histopathological damage in AA mice. Mechanistically, POG inhibited M2 macrophage polarization by downregulating key JAK2-STAT6-PPARγ axis factors. Conclusion: POG ameliorates AA by reducing type II immune factor release through JAK2-STAT6-PPARγ-mediated inhibition of M2 macrophage polarization. This study clarifies POG’s anti-AA mechanism and supports its clinical development.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: